Literature DB >> 16120121

Adenosine deaminase and 5'-nucleotidase activities in saliva from patients with oral and laryngeal cancer.

U Saracoglu1, O Guven, I Durak.   

Abstract

OBJECTIVE: The aim of this study was to evaluate saliva's activities of adenosine deaminase (ADA) and 5'-nucleotidase (5'-NT) enzymes and their utility as diagnostic and therapeutic markers in oral and laryngeal cancer.
MATERIALS AND METHODS: Pre- and post-operative saliva's activities of ADA and 5'-NT enzymes were measured in patients with squamous cell oral (n = 10) and laryngeal cancer (n = 17) and compared with control saliva samples (n = 19).
RESULTS: The ADA was found to be lower in saliva of the patients with oral cancer compared with the laryngeal cancer and controls. However, no significant differences were found between pre- and post-operative values for both enzymes in the patient groups. We also could not find statistically significant differences between saliva's activities of 5'-NT in patients and control subjects.
CONCLUSIONS: Low activity of ADA observed in saliva of the patients with oral cancer has been suggested as a compensatory mechanism against rapid purine and DNA metabolism in cancer cells. The current study does not support the hypothesis that saliva's activities of these enzymes may be used as additional diagnostic and prognostic cancer markers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16120121     DOI: 10.1111/j.1601-0825.2005.01131.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  2 in total

1.  Adenosine deaminase in saliva as a diagnostic marker of squamous cell carcinoma of tongue.

Authors:  Balwant Rai; Jasdeep Kaur; Reinhilde Jacobs; Suresh Chander Anand
Journal:  Clin Oral Investig       Date:  2010-04-09       Impact factor: 3.573

2.  ELISA based assays to measure adenosine deaminases concentration in serum and saliva for the diagnosis of ADA2 deficiency and cancer.

Authors:  Wenwen Luo; Liang Dong; Fenghong Chen; Wenbin Lei; Liya He; Qing Zhou; Thierry Lamy; Andrey V Zavialov
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.